When was Estuary Bio founded?

Estuary Bio was founded in 2022.

Where is Estuary Bio located?

Estuary Bio is headquartered in San Francisco, United States.

Is Estuary Bio a funded company?

Estuary Bio is a funded company, having raised a total of $144M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round.

When was the latest funding round of Estuary Bio?

Estuary Bio's latest funding was a $***** Series A round on Oct 16, 2026, with participation from 8 investors.

Where does Estuary Bio rank among its competitors?

Estuary Bio ranks 269th amongst 672 active competitors, of which 240 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Estuary Bio, which secured $93M in Oct, 2026.

Who are the top competitors of Estuary Bio?

Estuary Bio's top competitors include Alnylam, Forge Biologics and Strand Therapeutics. Among them, Estuary Bio secured the most recent funding round in October, 2026.

Estuary Bio - 2026 Company Profile, Funding & Competitors

Company Details

Developer of gene therapies for treating inherited polycystic kidney disease. These therapies utilize viral vectors to deliver functional genetic material directly to kidney cells. The approach aims to restore protein expression to address the underlying cause of cyst formation and organ damage. Research focuses on gene addition strategies to counteract specific mutations associated with the progression of this condition.

Website: estuarybio.com
Email ID: *****@estuarybio.com

Key Metrics

Founded Year

2022

Location

San Francisco, United States

Stage

Series A

Total Funding

$144M in 3 rounds

Latest Funding Round

Series A, Oct 16, 2026, $*****

Investors

Google Ventures & 7 more

Ranked

269^th among 672 active competitors

Similar Companies

Alnylam & 739 more

View Estuary Bio's full profile

Estuary Bio has raised a total funding of $144M over 3 rounds. Its latest funding round was a Series A round on Oct 16, 2026 for $*****. 8 investors participated in its latest round. Estuary Bio has 8 institutional investors.

Here is the list of recent funding rounds of Estuary Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 16, 2026	1030864	Series A	3520047	1365601	5762832	1641419
Jul 01, 2026	5730704	Series A	3373557	6695519	7674374	1283401

Access funding benchmarks and valuations. Sign up today!

View details of Estuary Bio's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Estuary Bio include Alnylam, Forge Biologics and Strand Therapeutics. Here is the list of Top 10 competitors of Estuary Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 14 others	81/100
2nd	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	72/100
3rd	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
4th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	69/100
5th	Ionis 1989, United States, Public	Developer of RNA-targeted medicines for various diseases	-	BB Biotech, Ojp & 1 others	69/100
6th	Stoke Therapeutics 2014, Bedford (United States), Public	Developer of antisense oligonucleotide drugs for treating inherited diseases by targeting RNA splicing	$131M	RTW Investments, Apple Tree Partners & 5 others	68/100
7th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of genome editing therapeutics using CRISPR and Cas9 technology	$85M	Atlas Venture, Novartis & 10 others	68/100
8th	Dyne Therapeutics 2017, Cambridge (United States), Public	Developer of nucleic acid therapies for rare diseases	$166M	Atlas Venture, Logos & 5 others	67/100
9th	Aspen Neuroscience 2018, San Diego (United States), Series C	Provider of genomic-based personalised pluripotent stem cell therapy	$339M	Revelation Partners, Orbimed & 22 others	67/100
10th	AviadoBio 2019, London (United Kingdom), Series A	Developer of gene therapies for neurodegenerative disorders	$80M	Monograph, New Enterprise Associates & 9 others	67/100
269th	Estuary Bio 2022, San Francisco (United States), Series A	Developer of gene therapies for treating inherited polycystic kidney disease	$144M	RA Capital Management, Deep Track Capital ... & 6 others	38/100